“Efficacy and Safety of Tislelizumab Plus Lenvatinib As First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma ”. 2024. Medical Forum Monthly 35 (6). http://medicalforummonthly.com/index.php/mfm/article/view/4698.